Juan Gimeno Blanes

List of Publications by Year
in descending order

132	15,603	57758	17105
papers	citations	44 h-index	122 g-index

154	154	154	13288
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure. Cardiovascular Research, 2022, 118, 1466-1478.	3.8	20
2	Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. European Heart Journal, 2022, 43, 3053-3067.	2.2	41
3	Impact of SARSâ€Covâ€2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure, 2022, 9, 2189-2198.	3.1	6
4	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 134-142.	4.0	3
5	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. ESC Heart Failure, 2021, 8, 95-105.	3.1	23
6	Computer versus cardiologist: Is a machine learning algorithm able to outperform an expert in diagnosing a phospholamban p.Arg14del mutation on the electrocardiogram?. Heart Rhythm, 2021, 18, 79-87.	0.7	26
7	Towards an Enhanced Tool for Quantifying the Degree of LV Hyper-Trabeculation. Journal of Clinical Medicine, 2021, 10, 503.	2.4	4
8	Filamin C variants are associated with a distinctive clinical and immunohistochemical arrhythmogenic cardiomyopathy phenotype. International Journal of Cardiology, 2020, 307, 101-108.	1.7	56
9	RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy. International Journal of Cardiology, 2020, 302, 124-130.	1.7	23
10	Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiology, 2020, 5, 73.	6.1	69
11	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circulation: Heart Failure, 2020, 13, e006832.	3.9	75
12	Trabeculated Myocardium in Hypertrophic Cardiomyopathy: Clinical Consequences. Journal of Clinical Medicine, 2020, 9, 3171.	2.4	5
13	ESC EORP Cardiomyopathy Registry: realâ€life practice of genetic counselling and testing in adult cardiomyopathy patients. ESC Heart Failure, 2020, 7, 3013-3021.	3.1	19
14	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	13.7	481
15	Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. ESC Heart Failure, 2020, 7, 3601-3609.	3.1	11
16	ALG12â€CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant. Molecular Genetics & Genomic Medicine, 2020, 8, e1304.	1.2	12
17	Genetic Factors Involved in Cardiomyopathies and in Cancer. Journal of Clinical Medicine, 2020, 9, 1702.	2.4	4
18	Genetics of feline hypertrophic cardiomyopathy. Clinical Genetics, 2020, 98, 203-214.	2.0	10

#	Article	IF	Citations
19	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. European Journal of Heart Failure, 2020, 22, 1076-1096.	7.1	96
20	Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart, 2019, 105, heartjnl-2018-313700.	2.9	31
21	Reply. Journal of the American College of Cardiology, 2019, 73, 1366-1367.	2.8	0
22	Sex-related differences in cardiomyopathies. International Journal of Cardiology, 2019, 286, 239-243.	1.7	39
23	A study of the pathogenicity of variants in familial heart disease. The value of cosegregation. American Journal of Translational Research (discontinued), 2019, 11, 1724-1735.	0.0	2
24	MiocardiopatÃa hipertrÃ³fica. Medicina ClÃnica, 2018, 150, 434-442.	0.6	5
25	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal, 2018, 39, 1784-1793.	2.2	94
26	Genetics of hypertrophic cardiomyopathy: A review of current state. Clinical Genetics, 2018, 93, 3-14.	2.0	130
27	Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 2457-2467.	2.8	59
28	D242N, a KV7.1 LQTS Mutation Uncovers a KEY Residue for IKS Voltage Dependence. Biophysical Journal, 2018, 114, 307a.	0.5	0
29	Phenotypic Characterization of a Family With An In-frame Deletion in the DMD Gene and Variable Penetrance. Current Gene Therapy, 2018, 18, 246-251.	2.0	2
30	Factores modificadores del fenotipo en la miocardiopatÃa hipertrÃ³fica. Respuesta. Revista Espanola De Cardiologia, 2018, 71, 770-771.	1.2	0
31	MiocardiopatÃa hipertrÃ³fica en 2018: Â¿en quÃ© punto estamos?. Cardiocore, 2018, 53, 148-151.	0.0	1
32	Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart, 2017, 103, 672-678.	2.9	71
33	COMPUTER ASSISTED RETINAL VESSEL TORTUOSITY EVALUATION IN NOVEL MUTATION FABRY DISEASE. Retina, 2017, 37, 592-603.	1.7	17
34	Value of the â€œStanding Testâ€•in the Diagnosis and Evaluation of Beta-blocker Therapy Response in Long QT Syndrome. Revista Espanola De Cardiologia (English Ed), 2017, 70, 907-914.	0.6	4
35	Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure. International Journal of Cardiology, 2017, 240, 265-270.	1.7	66
36	A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain. Revista Espanola De Cardiologia (English Ed), 2017, 70, 105-114.	0.6	10

#	Article	IF	Citations
37	Valor del Â«test de bipedestaciÃ³nÂ» en el diagnÃ³stico y la evaluaciÃ³n de la respuesta al tratamiento con bloqueadores beta en el sÃndrome de QT largo. Revista Espanola De Cardiologia, 2017, 70, 907-914.	1.2	2
38	Comentarios a los nuevos criterios internacionales para laÂinterpretaciÃ³n del electrocardiograma delÂdeportista. Revista Espanola De Cardiologia, 2017, 70, 983-990.	1.2	0
39	D242N, a KV7.1 LQTS mutation uncovers a key residue for IKs voltage dependence. Journal of Molecular and Cellular Cardiology, 2017, 110, 61-69.	1.9	11
40	Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. International Journal of Cardiology, 2017, 248, 232-238.	1.7	41
41	IKs Computational Modeling to Enforce the Investigation of D242N, a KV7.1 LQTS Mutation. , 2017, , .		0
42	An R1632C variant in the SCN5A gene causing Brugada syndrome. Molecular Medicine Reports, 2016, 13, 4677-4680.	2.4	3
43	Unclassifiable arrhythmic cardiomyopathy associated with Emeryâ€“Dreifuss caused by a mutation in <scp>FHL1</scp>. Clinical Genetics, 2016, 90, 171-176.	2.0	19
44	Individualized therapy in patients with Fabry disease: is it a feasible strategy for rare diseases?. Expert Opinion on Orphan Drugs, 2016, 4, 1199-1206.	0.8	0
45	Factor de transcripciÃ³n TBX1 en el remodelado cardiaco asociado al infarto de miocardio. Revista Espanola De Cardiologia, 2016, 69, 1042-1050.	1.2	1
46	The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1042-1050.	0.6	0
47	Mutation in <scp>JPH2</scp> cause dilated cardiomyopathy. Clinical Genetics, 2016, 90, 468-469.	2.0	20
48	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. Journal of the American College of Cardiology, 2016, 68, 2440-2451.	2.8	340
49	La importancia del estudio familiar y genÃ©tico: la mutaciÃ³n p.L3778F en el receptor de la rianodina probablemente no cause un fenotipo tan grave. Revista Espanola De Cardiologia, 2016, 69, 702-704.	1.2	1
50	Penetrancia familiar en la parada cardÃaca en ausencia de cardiopatÃa aparente: observaciones del estudio FIVI-Gen. Cardiocore, 2016, 51, 30-36.	0.0	2
51	The Importance of Family-genetic Screening: The Phenotype Caused by the p.L3778F Ryanodine Receptor Mutation is Likely Less Severe Than Previously Thought. Revista Espanola De Cardiologia (English Ed), 2016, 69, 702-704.	0.6	0
52	Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	19
53	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal, 2016, 37, 1850-1858.	2.2	757
54	Hypertrophic or hypertensive cardiomyopathy?. International Journal of Cardiology, 2016, 203, 891-892.	1.7	3

#	Article	IF	Citations
55	Plan of Action for Inherited Cardiovascular Diseases: Synthesis of Recommendations and Action Algorithms. Revista Espanola De Cardiologia (English Ed), 2016, 69, 300-309.	0.6	14
56	Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 625-635.	0.6	60
57	Prediction of thromboâ€embolic risk in patients with hypertrophic cardiomyopathy (<scp>HCM</scp>) Tj ETQq1 1 0.784314 rgBT /Ov	7.1	114
58	Author's reply. Europace, 2015, 17, 334-337.	1.7	0
59	A mutation in the Zâ€line Cypher/ZASP protein is associated with arrhythmogenic right ventricular cardiomyopathy. Clinical Genetics, 2015, 88, 172-176.	2.0	28
60	Phenotype and prognostic correlations of the converter region mutations affecting the Î² myosin heavy chain. Heart, 2015, 101, 1047-1053.	2.9	54
61	New haplotype of Fabry disease among patients screened for left ventricular hypertrophy of unknown cause. Molecular Genetics and Metabolism, 2015, 114, S29-S30.	1.1	0
62	Arrhythmogenic right ventricular cardiomyopathy. Lancet, The, 2015, 385, 662.	13.7	4
63	Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm, 2015, 12, 766-773.	0.7	111
64	Unexpected autopsy findings after sudden cardiac death: Cardiovascular myxoedema and endocardial fibroelastosis. International Journal of Cardiology, 2015, 182, 281-283.	1.7	4
65	Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study). American Journal of Cardiology, 2015, 116, 894-899.	1.6	46
66	The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. European Heart Journal, 2015, 36, 1367-1370.	2.2	75
67	MutaciÃ³n p.Arg14del en fosfolambÃ¡n en una familia espaÃ±ola con miocardiopatÃa arritmogÃ©nica: evidencia de una mutaciÃ³n europea fundadora. Revista Espanola De Cardiologia, 2015, 68, 346-349.	1.2	7
68	Phospholamban p.arg14del Mutation in a Spanish Family With Arrhythmogenic Cardiomyopathy: Evidence for a European Founder Mutation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 346-349.	0.6	6
69	Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing. Revista Espanola De Cardiologia (English Ed), 2015, 68, 861-868.	0.6	2
70	Fenotipo heterogÃ©neo del sÃndrome de QT largo causado por la mutaciÃ³n KCNH2-H562R: importancia del estudio genÃ©tico familiar. Revista Espanola De Cardiologia, 2015, 68, 861-868.	1.2	6
71	A newKCNQ1mutation at the S5 segment that impairs its association with KCNE1 is responsible for short QT syndrome. Cardiovascular Research, 2015, 107, 613-623.	3.8	67
72	Hypertrophic Obstructive Cardiomyopathy and Takotsubo Syndrome: Could They Coexist?. Archives of Cardiovascular Imaging, 2015, 3, .	0.2	0

#	Article	IF	Citations
73	CRT-177 Ulnar Artery, is it as Safe as the Radial for Cardiac Catheterization?. JACC: Cardiovascular Interventions, 2014, 7, S32.	2.9	1
74	Comprehensive clinical evaluation of a large Spanish family with Anderson-Fabry disease, novel GLA mutation and severe cardiac phenotype. Medicina ClÃnica, 2014, 142, 497-504.	0.6	5
75	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.2	3,469
76	A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.2	848
77	Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2014, 35, 2279-2284.	2.2	154
78	Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: characterizing a phenotype. Europace, 2014, 16, 1838-1846.	1.7	87
79	A study of the <scp>SCN5A</scp> gene in a cohort of 76 patients with Brugada syndrome. Clinical Genetics, 2013, 83, 530-538.	2.0	17
80	Eco-Doppler de ejercicio en pacientes con miocardiopatÃa hipertrÃ³fica. Factores determinantes de la limitaciÃ³n funcional. Revista Espanola De Cardiologia, 2013, 66, 98-103.	1.2	12
81	Exercise Eco-Doppler in Hypertrophic Cardiomyopathy Patients. Determinant Factors of Exercise Intolerance. Revista Espanola De Cardiologia (English Ed), 2013, 66, 98-103.	0.6	4
82	Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 1448-1458.	2.2	346
83	Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. Nature Medicine, 2013, 19, 193-201.	30.7	296
84	Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. European Heart Journal, 2013, 34, 2529-2537.	2.2	84
85	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 2636-2648.	2.2	2,436
86	Atypical Cause of Syncope in Patients with Brugada Syndrome. The European Journal of Cardiovascular Medicine, 2013, 11, .	1.0	0
87	Somatic <i>MYH7</i>, <i>MYBPC3</i>, <i>TPM1</i>, <i>TNNT2</i> and <i>TNNI3</i> Mutations in Sporadic Hypertrophic Cardiomyopathy. Circulation Journal, 2013, 77, 2358-2365.	1.6	15
88	Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: An Opportunity to Be Taken. Revista Espanola De Cardiologia (English Ed), 2012, 65, 314-318.	0.6	6
89	AblaciÃ³n septal alcohÃ³lica en la miocardiopatÃa hipertrÃ³fica, una oportunidad para aprovechar. Revista Espanola De Cardiologia, 2012, 65, 314-318.	1.2	11
90	Percutaneous coronary intervention with rotational atherectomy for severely calcified unprotected left main: Immediate and twoâ€years followâ€up results. Catheterization and Cardiovascular Interventions, 2012, 80, 215-220.	1.7	36

#	Article	IF	Citations
91	Short QT and dilated cardiomyopathy. A phenotype with a good prognosis?. International Journal of Cardiology, 2011, 151, 356-357.	1.7	0
92	Hypertrophic cardiomyopathy or storage cardiomyopathy? Role of genetics to predict outcome. International Journal of Cardiology, 2011, 151, 380-381.	1.7	0
93	Modelo de intervenciÃ³n coronaria percutÃ¡nea primaria en la RegiÃ³n de Murcia. Revista Espanola De Cardiologia Suplementos, 2011, 11, 28-34.	0.2	2
94	Efficacy of percutaneous closure of patent foramen ovale: comparison among three commonly used occluders. Heart, 2011, 97, 394-399.	2.9	42
95	Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. Heart, 2010, 96, 1980-1984.	2.9	58
96	Characteristics of Sudden Death in Inherited Heart Disease. Revista Espanola De Cardiologia (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	2
97	Intervencionismo coronario en lesiones severamente calcificadas mediante aterectomÃa rotacional y stent liberador de paclitaxel: resultados tras un aÃ±o de seguimiento. Revista Espanola De Cardiologia, 2010, 63, 107-110.	1.2	27
98	CaracterÃsticas de la muerte sÃºbita en las cardiopatÃas hereditarias. Revista Espanola De Cardiologia, 2010, 63, 268-276.	1.2	11
99	Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2009, 7, 82-90.	1.0	42
100	Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. European Heart Journal, 2009, 30, 2599-2605.	2.2	160
101	Penetrance and Risk Profile in Inherited Cardiac Diseases Studied in a Dedicated Screening Clinic. American Journal of Cardiology, 2009, 104, 406-410.	1.6	38
102	Heat stroke, an unusual trigger of Brugada electrocardiogram. American Journal of Emergency Medicine, 2009, 27, 634.e1-634.e3.	1.6	11
103	Unusual presentation of acute coronary syndrome. Bilateral coronary dissection after car accident. American Journal of Emergency Medicine, 2009, 27, 1024.e3-1024.e5.	1.6	7
104	Embolia coronaria tras implante percutÃ¡neo de prÃ³tesis valvular aÃ³rtica. Revista Espanola De Cardiologia, 2009, 62, 1074-1075.	1.2	4
105	Gadolinium-Enhanced Cardiovascular Magnetic Resonance and Exercise Capacity in Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2008, 61, 853-860.	0.6	1
106	Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation. Journal of the American College of Cardiology, 2008, 51, 818-825.	2.8	256
107	Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. American Heart Journal, 2008, 156, 85-91.	2.7	80
108	Prognostic value of the Thrombolysis in Myocardial Infarction risk score in a unselected population with chest pain. Construction of a new predictive model. American Journal of Emergency Medicine, 2008, 26, 439-445.	1.6	8

#	Article	IF	Citations
109	Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications. Journal of Cardiac Failure, 2008, 14, 414-419.	1.7	33
110	Detection and estimation of T wave alternans with matched filter and nonparametric bootstrap test. , 2008, , .		2
111	Prevalence, Clinical Significance, and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype. Journal of the American College of Cardiology, 2007, 49, 2419-2426.	2.8	167
112	Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2007, 50, 2399-2403.	2.8	254
113	Implantable Cardioverter Defibrillator and Hypertrophic Cardiomyopathy. Experience at Three Centers. Revista Espanola De Cardiologia (English Ed), 2006, 59, 537-544.	0.6	11
114	In-Hospital and Long-Term Mortality in Women With Acute Myocardial Infarction Treated by Primary Angioplasty. Revista Espanola De Cardiologia (English Ed), 2006, 59, 1113-1122.	0.6	16
115	Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. European Heart Journal, 2006, 27, 3073-3073.	2.2	34
116	Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels to Predict Exercise Capacity in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2006, 98, 515-519.	1.6	42
117	Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. European Heart Journal, 2006, 27, 1933-1941.	2.2	352
118	Heterophile antibodies produce spuriously elevated concentrations of cardiac Troponin I in patients with Legionella pneumophila. Clinical Biochemistry, 2005, 38, 584-587.	1.9	14
119	Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart, 2005, 92, 785-791.	2.9	235
120	Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart, 2005, 91, 920-925.	2.9	126
121	Natural history and familial characteristics of isolated left ventricular non-compaction. European Heart Journal, 2005, 26, 187-192.	2.2	427
122	Backscatter evaluation of myocardial functional and textural findings in children with right ventricular pressure and/or volume overload. American Journal of Cardiology, 2004, 93, 594-597.	1.6	12
123	Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. Journal of the American College of Cardiology, 2004, 44, 398-405.	2.8	72
124	Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 873-879.	2.8	484
125	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 209-216.	8.2	169
126	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 209-216.	8.2	278

#	Article	IF	Citations
127	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 925-925.	8.2	0
128	Reversal of Acute Pulmonary Oedema with Beta-blockers in Hypertrophic Cardiomyopathy. European Journal of Echocardiography, 2003, 4, 71-72.	2.3	0
129	Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. Journal of the American College of Cardiology, 2002, 40, 1445-1450.	2.8	285
130	Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet, The, 2001, 357, 420-424.	13.7	436
131	Soluble and Particulate Organophosphorus Neuropathy Target Esterase in Brain and Sciatic Nerve of the Hen, Cat, Rat, and Chick. Journal of Neurochemistry, 1993, 61, 2164-2168.	3.9	16
132	Evidence for reciprocal network interactions between injured hearts and cancer. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	2